These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 9758239

  • 1. Advances in pharmacotherapy for obesity.
    Carruba M, Tomello C, Briscini L, Nisoli E.
    Int J Obes Relat Metab Disord; 1998 Aug; 22 Suppl 1():S13-6; discussion S17. PubMed ID: 9758239
    [Abstract] [Full Text] [Related]

  • 2. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.
    Weyer C, Gautier JF, Danforth E.
    Diabetes Metab; 1999 Mar; 25(1):11-21. PubMed ID: 10335419
    [Abstract] [Full Text] [Related]

  • 3. Anti-obesity and anti-diabetic activities of a new beta3 adrenergic receptor agonist, (S)-(Z)-[4-[[1-[2-[(2-hydroxy-3-phenoxypropyl)]amino]ethyl]-1-propenyl] phenoxy] acetic acid ethanedioic acid (SWR-0342SA), in KK-Ay mice.
    Kiso T, Namikawa T, Tokunaga T, Sawada K, Kakita T, Shogaki T, Ohtsubo Y.
    Biol Pharm Bull; 1999 Oct; 22(10):1073-8. PubMed ID: 10549858
    [Abstract] [Full Text] [Related]

  • 4. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
    Astrup A, Lundsgaard C.
    Exp Clin Endocrinol Diabetes; 1998 Oct; 106 Suppl 2():29-34. PubMed ID: 9792479
    [Abstract] [Full Text] [Related]

  • 5. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog.
    Hicks A, McCafferty GP, Riedel E, Aiyar N, Pullen M, Evans C, Luce TD, Coatney RW, Rivera GC, Westfall TD, Hieble JP.
    J Pharmacol Exp Ther; 2007 Oct; 323(1):202-9. PubMed ID: 17626794
    [Abstract] [Full Text] [Related]

  • 6. Agonist interactions with chimeric and mutant beta1- and beta3-adrenergic receptors: involvement of the seventh transmembrane region in conferring subtype specificity.
    Granneman JG, Lahners KN, Zhai Y.
    Mol Pharmacol; 1998 May; 53(5):856-61. PubMed ID: 9584211
    [Abstract] [Full Text] [Related]

  • 7. Evidence for a secondary state of the human beta3-adrenoceptor.
    Baker JG.
    Mol Pharmacol; 2005 Dec; 68(6):1645-55. PubMed ID: 16129733
    [Abstract] [Full Text] [Related]

  • 8. Ligand-directed signaling at the beta3-adrenoceptor produced by 3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) relative to receptor agonists.
    Sato M, Horinouchi T, Hutchinson DS, Evans BA, Summers RJ.
    Mol Pharmacol; 2007 Nov; 72(5):1359-68. PubMed ID: 17717109
    [Abstract] [Full Text] [Related]

  • 9. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods.
    Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatano A, Takahashi K, Nomura S.
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1367-73. PubMed ID: 10027879
    [Abstract] [Full Text] [Related]

  • 10. 2-Amino-4-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridines: novel selective beta3-adrenoceptor agonists.
    Zheng W, Nikulin VI, Konkar AA, Vansal SS, Shams G, Feller DR, Miller DD.
    J Med Chem; 1999 Jun 17; 42(12):2287-94. PubMed ID: 10377236
    [Abstract] [Full Text] [Related]

  • 11. Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.
    Lafontaine JA, Day RF, Dibrino J, Hadcock JR, Hargrove DM, Linhares M, Martin KA, Maurer TS, Nardone NA, Tess DA, Dasilva-Jardine P.
    Bioorg Med Chem Lett; 2007 Sep 15; 17(18):5245-50. PubMed ID: 17632003
    [Abstract] [Full Text] [Related]

  • 12. Functional domains of the mouse beta3-adrenoceptor associated with differential G protein coupling.
    Sato M, Hutchinson DS, Bengtsson T, Floren A, Langel U, Horinouchi T, Evans BA, Summers RJ.
    J Pharmacol Exp Ther; 2005 Dec 15; 315(3):1354-61. PubMed ID: 16144970
    [Abstract] [Full Text] [Related]

  • 13. Antiobesity and antidiabetic beta-agonists: lessons learned and questions to be answered.
    Yen TT.
    Obes Res; 1994 Sep 15; 2(5):472-80. PubMed ID: 16353599
    [Abstract] [Full Text] [Related]

  • 14. Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents.
    Arch JR, Ainsworth AT, Ellis RD, Piercy V, Thody VE, Thurlby PL, Wilson C, Wilson S, Young P.
    Int J Obes; 1984 Sep 15; 8 Suppl 1():1-11. PubMed ID: 6152555
    [Abstract] [Full Text] [Related]

  • 15. Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle.
    Fujimura T, Tamura K, Tsutsumi T, Yamamoto T, Nakamura K, Koibuchi Y, Kobayashi M, Yamaguchi O.
    J Urol; 1999 Feb 15; 161(2):680-5. PubMed ID: 9915482
    [Abstract] [Full Text] [Related]

  • 16. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.
    Arch JR.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Aug 15; 378(2):225-40. PubMed ID: 18612674
    [Abstract] [Full Text] [Related]

  • 17. The beta3-adrenoceptor agonist 4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-benzenesulfonamide (L755507) and antagonist (S)-N-[4-[2-[[3-[3-(acetamidomethyl)phenoxy]-2-hydroxypropyl]amino]-ethyl]phenyl]benzenesulfonamide (L748337) activate different signaling pathways in Chinese hamster ovary-K1 cells stably expressing the human beta3-adrenoceptor.
    Sato M, Hutchinson DS, Evans BA, Summers RJ.
    Mol Pharmacol; 2008 Nov 15; 74(5):1417-28. PubMed ID: 18684840
    [Abstract] [Full Text] [Related]

  • 18. Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors.
    Molenaar P, Sarsero D, Arch JR, Kelly J, Henson SM, Kaumann AJ.
    Br J Pharmacol; 1997 Jan 15; 120(2):165-76. PubMed ID: 9117106
    [Abstract] [Full Text] [Related]

  • 19. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, Van der Ploeg LH, Goulet MT, Hagmann WK, Lin LS, Lanza TJ, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Francis B, Strack AM, MacIntyre DE, Shearman LP.
    J Pharmacol Exp Ther; 2007 Jun 15; 321(3):1013-22. PubMed ID: 17327489
    [Abstract] [Full Text] [Related]

  • 20. The biochemical effect of the naturally occurring Trp64-->Arg mutation on human beta3-adrenoceptor activity.
    Piétri-Rouxel F, St John Manning B, Gros J, Strosberg AD.
    Eur J Biochem; 1997 Aug 01; 247(3):1174-9. PubMed ID: 9288945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.